| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mi | No patent protection for Stelara? No problem for J&J as Tremfya fills the void | ||
| Mi | Buzzy Veradermics shows its oral minoxidil can tackle female pattern hair loss, too | ||
| Mi | Kelun scores sac-TMT win in first-line NSCLC population missing from Merck's massive phase 3 program | ||
| Mi | Sanofi teams up with Special Olympics Unified Football World, raises respiratory health awareness | ||
| 14.07. | With FDA approval for its breast cancer blockbuster hopeful, Celcuity could 'belong in the hands' of a Big Pharma | ||
| 14.07. | Director's Note on What to Expect at the 2026 Partnerships with Sites Summit | ||
| 14.07. | Inside agency view: Havas SO on authenticity, connection and pushing back against the 'sea of sameness' | ||
| 14.07. | Huyabio scores with Opdivo combo in 'milestone' skin cancer trial | ||
| 14.07. | AstraZeneca pays up to $1.5B for EGFR lung cancer drug Zegfrovy from its spinoff Dizal | ||
| 14.07. | Real Chemistry builds body of AI healthcare commercialization tools with Anatomi launch | ||
| 13.07. | FDA's latest onshoring move homes in on streamlined facility registration, foreign plant scrutiny | ||
| 13.07. | Lupin recalls more than 2.5M prescription eye drop bottles, citing possible contamination | ||
| 13.07. | GSK to seek FDA approval for Jemperli in small but high-profile cancer use after phase 2 win | ||
| 13.07. | Germany pushes through healthcare reform package despite pharma's drug discount resistance | ||
| 10.07. | Star Padcev-Keytruda combo expands bladder cancer reach with FDA approval, pressuring AstraZeneca | ||
| 10.07. | Young people living with PKU take the mic in BioMarin podcast series, TikTok push | ||
| 10.07. | Apollo inks €3B equity deal for stake in Bayer's contraceptives business | ||
| 10.07. | FDA rejects Hengrui, Elevar's PD-1 liver cancer combo for a 3rd time | ||
| 10.07. | Sanofi snags FDA thumbs up for Sarclisa as 1st cancer drug delivered by on-body injector | ||
| 10.07. | Fierce Pharma Asia-More AstraZeneca China deals; Kailera, Hengrui's oral GLP-1 data; Scrutiny of Chinese trials | ||
| 10.07. | J&J's Tremfya retakes ad spending throne in June as Haleon tops pharma's World Cup airings | ||
| 09.07. | AstraZeneca, Ionis shares tumble on ATTR-CM trial flop, but analyst flags over-reaction | ||
| 09.07. | In compensation push, HHS gears up to draft COVID vaccine injury table | ||
| 09.07. | Ipsen's Botox rival Dysport charts new horizons with dual phase 3 wins in migraine | ||
| 09.07. | Novo Nordisk asks public to 'Meet Me in the Middle' in new obesity experience installation |